EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimating the Potential Public Health Value of BCG Revaccination

Rebecca A Clark iD, Tom Sumner iD, Chathika K Weerasuriya iD, Roel Bakker iD, Thomas J Scriba iD, Richard G White iD

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Rebecca A Clark und 5 weiteren Autor:innen. Beteiligte Einrichtung: TB Modelling Group and TB Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom. Hauptthemen laut MEDLINE: Tuberculosis, BCG Vaccine, Public Health, Immunization, Secondary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Edinburgh, Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An upcoming trial may provide further evidence that adolescent/adult-targeted BCG revaccination prevents sustained Mycobacterium tuberculosis infection, but its public health value depends on its impact on overall tuberculosis morbidity and mortality, which will remain unknown. Using previously calibrated models for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection efficacy, and we evaluated scenarios varying additional prevention-of-disease efficacy between +50% (reducing risk) and −50% (increasing risk). Given the assumed prevention-of-infection efficacy and range in prevention-of-disease efficacy, BCG revaccination may have a positive health impact and be cost-effective. This may be useful when considering future evaluations and implementation of adolescent/adult BCG revaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisBCG VaccinePublic HealthImmunization, SecondaryHumansSouth AfricaAdolescentIndiaAdultCost-Benefit AnalysisChildYoung AdultInfantChild, PreschoolMycobacterium tuberculosis

Stichwörter der Autor:innen

BCG revaccinationhealth and economic impactmathematical modellingtuberculosisvaccines

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • TB Modelling Group and TB Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • Vaccine Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • KNCV Tuberculosis Foundation, Division TB Elimination and Health System Innovations, the Hague, the Netherlands.
  • South African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Rebecca A Clark, Tom Sumner, Chathika K Weerasuriya, Roel Bakker, Thomas J Scriba, Richard G White

Förderung

  • University of Edinburgh
  • Engineering and Physical Sciences Research Council

Zitieren

APA

Clark, R. A., Sumner, T., Weerasuriya, C. K., Bakker, R., Scriba, T. J., & White, R. G. (2024). Estimating the Potential Public Health Value of BCG Revaccination. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae089

Vancouver

Clark RA, Sumner T, Weerasuriya CK, Bakker R, Scriba TJ, White RG. Estimating the Potential Public Health Value of BCG Revaccination. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae089

BibTeX
@article{Clark2024,
  author = {Clark, Rebecca A and Sumner, Tom and Weerasuriya, Chathika K and Bakker, Roel and Scriba, Thomas J and White, Richard G},
  title = {Estimating the Potential Public Health Value of BCG Revaccination},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae089}
}
Kostenlos starten →